Emmes CRO acquires Orphan Reach

By The Science Advisory Board staff writers

May 14, 2021 -- Clinical Research Organization (CRO) Emmes, a portfolio company of Behrman Capital, announced it has acquired Orphan Reach, an organization specialized in clinical research related to rare diseases.

This marks Emmes' second acquisition since Behrman's investment in 2019 and builds on its recent acquisition of Neox S.R.O. in December 2020, the company stated in a release. Orphan Reach was founded about 20 years ago and has offices in Ireland, Germany, India, Canada, and the U.S.

Financial terms of the transaction were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.